Gilead Sciences (CYPH) discloses 0% beneficial stake in Cypherpunk Technologies

Rhea-AI Filing Summary

Cypherpunk Technologies Inc. (CYPH) is the subject of an amended Schedule 13G filing by Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.

Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.

Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.

FAQ

What does Gilead Sciences report about its ownership of Cypherpunk Technologies (CYPH)?

Gilead Sciences reports beneficial ownership of 0 shares of Cypherpunk Technologies common stock, representing 0% of the class. The Schedule 13G/A confirms Gilead has no sole or shared voting or dispositive power over CYPH shares.

Why did Gilead Sciences file an amended Schedule 13G/A for CYPH?

Gilead filed the amended Schedule 13G/A to report that it now beneficially owns 0 shares, or 0% of Cypherpunk’s common stock. The filing reflects that its holdings have fallen to 5 percent or less of the class.

What class of securities does the Gilead filing cover for Cypherpunk Technologies (CYPH)?

The filing covers Cypherpunk Technologies’ common stock, with a par value of $0.001 per share and CUSIP number 52187K200. All reported ownership and percentage figures in the Schedule 13G/A relate specifically to this class.

Does Gilead Sciences seek to influence control of Cypherpunk Technologies (CYPH)?

Gilead certifies that any Cypherpunk securities referenced were acquired and are held in the ordinary course of business. It states they were not acquired or held to change or influence control of Cypherpunk or in any transaction designed for that purpose.

What voting and dispositive powers over CYPH shares does Gilead report?

Gilead reports 0 shares with sole voting power, 0 with shared voting power, 0 with sole dispositive power, and 0 with shared dispositive power. This indicates no reported ability to vote, sell, or direct the disposition of any CYPH shares.

Who signed the Gilead Schedule 13G/A related to Cypherpunk Technologies?

The Schedule 13G/A was signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc. The signature certifies that the information in the ownership statement is true, complete, and correct.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:35 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CYPHERPUNK TECHNOLOGIES INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

52187K200

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 52187K200

1

Names of Reporting Persons

GILEAD SCIENCES, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CYPHERPUNK TECHNOLOGIES INC.
(b)	Address of issuer's principal executive offices: 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts, 02141
Item 2.
(a)	Name of person filing: Gilead Sciences, Inc.
(b)	Address or principal business office or, if none, residence: 333 Lakeside Drive Foster City, California 94404
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 52187K200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GILEAD SCIENCES, INC.

Signature:	/s/ Andrew D. Dickinson
Name/Title:	Andrew D. Dickinson, Executive Vice President and Chief Financial Officer
Date:	02/12/2026